The five-year deal governs user fees the industry pays the FDA to fund product reviews. Revenue including those fees is expected to total $1.9 billion, the report said, about double the current version’s amount.
The current agreement is set to expire in September.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.